MarketCap
Facebook
X
Telegram
Halozyme Therapeutics Net Debt | HALO
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Halozyme Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.01 B | 1.39 B | 1.38 B | 1.27 B | 758 M | 646 M | 282 M | 68.4 M | 33.6 M | 150 M | 6.54 M | 62.7 M | 66.6 M | -68.8 M | -52.8 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.01 B | -68.8 M | 534 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
-121 M | $ 51.0 | 1.83 % | $ 1.48 B |  USA |
 |
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
-2.21 M | $ 1.88 | 0.53 % | $ 107 M | USA |
 |
Clovis Oncology
CLVS
|
293 M | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-127 M | - | - | $ 401 M | USA |
 |
Evelo Biosciences
EVLO
|
-2.07 M | - | -14.46 % | $ 27.9 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
-1.3 B | $ 60.26 | 0.06 % | $ 11.6 B | USA |
 |
BioNTech SE
BNTX
|
-7.45 B | $ 98.52 | 0.24 % | $ 23.8 B |  Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-5.46 M | $ 2.17 | 0.46 % | $ 3.57 M |  Israel |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-41.4 M | - | - | $ 384 M |  Britain |
 |
Genocea Biosciences
GNCA
|
-30.7 M | - | -15.0 % | $ 3.04 M | USA |
 |
Catalyst Biosciences
CBIO
|
-36.1 M | $ 13.99 | 0.84 % | $ 1.25 B | USA |
 |
C4 Therapeutics
CCCC
|
-14.6 M | $ 2.98 | 0.3 % | $ 247 M | USA |
 |
Codexis
CDXS
|
-7.74 M | $ 1.32 | 1.09 % | $ 115 M | USA |
 |
Amryt Pharma plc
AMYT
|
-107 M | - | - | $ 621 M | Britain |
 |
Cerus Corporation
CERS
|
-6.9 M | $ 2.62 | 0.38 % | $ 499 M | USA |
 |
G1 Therapeutics
GTHX
|
19.1 M | - | - | $ 370 M | USA |
 |
Coherus BioSciences
CHRS
|
-85.6 M | $ 1.13 | 0.43 % | $ 132 M | USA |
 |
Celldex Therapeutics
CLDX
|
-26.5 M | $ 31.1 | 1.16 % | $ 2.07 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-2.74 M | $ 4.25 | 3.16 % | $ 51.9 M | Israel |
 |
Cellectar Biosciences
CLRB
|
-12.8 M | $ 1.8 | 0.72 % | $ 4.69 M | USA |
 |
AbbVie
ABBV
|
59.5 B | $ 264.34 | 0.09 % | $ 468 B | USA |
 |
Humanigen
HGEN
|
-45 M | - | -81.12 % | $ 4.28 M | USA |
 |
Cocrystal Pharma
COCP
|
-5.52 M | $ 1.17 | 1.74 % | $ 13.2 M | USA |
 |
AbCellera Biologics
ABCL
|
14.7 M | $ 12.7 | 0.4 % | $ 3.79 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
-69.8 M | $ 5.4 | 2.65 % | $ 286 M | USA |
 |
Collegium Pharmaceutical
COLL
|
-226 M | $ 22.53 | 0.2 % | $ 713 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
-114 M | $ 116.1 | 4.93 % | $ 12.1 B | USA |
 |
Фармсинтез
LIFE
|
612 M | - | - | - |  Russia |
 |
IGM Biosciences
IGMS
|
18.7 M | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
-19.8 M | - | - | $ 13.1 M | Canada |
 |
Kinnate Biopharma
KNTE
|
-53.8 M | - | - | $ 123 M | USA |
 |
Cardiff Oncology
CRDF
|
-16.6 M | $ 1.24 | 0.74 % | $ 82.9 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-12.1 M | - | - | $ 231 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-14 M | $ 7.14 | 0.19 % | $ 95.1 M | USA |
 |
Karuna Therapeutics
KRTX
|
-169 M | - | - | $ 12.2 B | USA |
 |
Curis
CRIS
|
-3.44 M | $ 0.83 | 1.1 % | $ 10.9 M | USA |
 |
CorMedix
CRMD
|
-143 M | $ 7.85 | 1.03 % | $ 565 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-53 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-141 M | $ 54.23 | 0.23 % | $ 4.88 B |  Schweiz |
|
Champions Oncology
CSBR
|
-3.34 M | $ 4.9 | 0.1 % | $ 67.8 M | USA |
 |
Chimerix
CMRX
|
-29.9 M | - | - | $ 756 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-3.64 M | $ 11.62 | 8.21 % | $ 918 M | USA |
 |
Cue Biopharma
CUE
|
-22.9 M | $ 31.41 | 1.45 % | $ 2.98 B | USA |
 |
CEL-SCI Corporation
CVM
|
-5.1 M | $ 1.67 | 2.38 % | $ 13.4 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-35 M | $ 4.85 | 0.2 % | $ 929 M | Canada |
 |
Cytokinetics, Incorporated
CYTK
|
143 M | $ 64.66 | 0.17 % | $ 7.77 M | USA |
 |
Daré Bioscience
DARE
|
-23.5 M | $ 0.78 | 4.73 % | $ 8.72 M | USA |
 |
Adagene
ADAG
|
-73.3 M | $ 2.93 | 2.86 % | $ 173 M |  China |
 |
DiaMedica Therapeutics
DMAC
|
-15.5 M | $ 7.94 | 1.4 % | $ 373 M | USA |